CJC-1295 with DAC
CJC-1295 with DAC (Drug Affinity Complex)
What is CJC-1295 with DAC?
CJC-1295 with DAC: Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release. The sources cited here most often discuss it for: Days-long GH and IGF-1 rise; Visceral fat, trial halted; Sleep, muscle and fat, unproven claims. Evidence label: Early human.
- Type
- Peptide
- Family
- Growth Hormone Axis
- Evidence label
- Early human (3 of 5)
- Regulatory status
- FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn.
- Goals discussed
- Hormones & Fertility, Fat Loss & Metabolism, Sleep, Muscle & Tone
- Also called
- DAC:GRF, CJC-1295 with DAC
- Last reviewed
- 2026-10-11
- Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release; not FDA-approved, development halted in 2006.12
Regulatory status FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn. 3
After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.
Two randomized, placebo-controlled, ascending-dose trials in healthy adults aged 21 to 61.
What is CJC-1295 with DAC researched for?
The three outcomes most discussed for CJC-1295 with DAC in the sources below, as those sources report them. humanpeptides.fyi makes no claims of its own: a listed benefit can be unproven or can have failed in trials, and the label on each line says which.
Sleep, muscle and fat, unproven claims
- Claimed sleep, muscle and abdominal fat-loss benefits are extrapolated from GH/IGF-1 elevation and GHRH research; no dedicated CJC-1295 outcome studiespractitioner/vendor review6
What do researchers and users say about CJC-1295 with DAC?
FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
FDA's safety assessment of CJC-1295 as a nominated compounding substance; the nomination was later withdrawn.
What side effects of CJC-1295 with DAC are reported?
- Injection-site pain/swelling/itching, induration, headache, diarrhea, hypertension (Teichman RCTs); also flushing, water retention, insomnia reported67
- A trial participant died of myocardial infarction after 11th dose (attributed to pre-existing coronary disease), program stopped2
- Serious adverse events including increased heart rate and a systemic vasodilatory reactionFDA assessment3
- Possible immune reactions (immunogenicity) and peptide impurity problems in compounded productsFDA assessment3
What do peptide guides say about CJC-1295 with DAC?
- Dr. Axe Dr. Axe's guide lists the CJC-1295 and ipamorelin pairing as research-only with insufficient evidence, notes the cited human study tested CJC-1295 alone, and says WADA bans CJC-1295. 8
- PepEdHub PepEdHub explains the DAC version binds albumin, stretching its half-life to roughly 6 to 8 days, and that its more sustained GH release may raise IGF-1 more than the short-acting form. 9
- Seek Peptides Seek Peptides groups CJC-1295 with and without DAC in one entry aimed at sustained GH elevation, promoting it for muscle, recovery, sleep and fat loss, usually paired with ipamorelin. 10
What does the research say, system by system?
Body & tissues1
- No direct tissue outcome data found
Hormones & physiology2
Brain, mood & sleep1
- No direct CJC-1295 sleep study; parent hormone GHRH (intranasal, 1999 human study) increased slow-wave and REM sleep, extrapolated to CJC-1295 (indirect)6
Weight & metabolism1
- Visceral obesity trial halted before resultshuman5
Muscle1
- No outcome data; theorized via GH/IGF-1 elevation1
Also notable1
- WADA lists CJC-1295 as an S2 prohibited substance; a 2005 rat study and GHRH-knockout mouse study support GH release and normal growthanimal6
How strong is the evidence for CJC-1295 with DAC?
Small human PK/PD RCTs showing GH/IGF-1 rise; no clinical outcome data; development abandoned
Small, short, old, unblinded or single-group human studies. How tiers work
Questions about CJC-1295 with DAC
What is CJC-1295 with DAC?
Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release.
Is CJC-1295 with DAC FDA-approved?
FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn.
What is CJC-1295 with DAC researched for?
The sources cited on this page most often discuss three outcomes: Days-long GH and IGF-1 rise; Visceral fat, trial halted; Sleep, muscle and fat, unproven claims. Each line above shows what the source reports and how strong that evidence is.
What side effects of CJC-1295 with DAC are reported?
Reported in the cited sources: Injection-site pain/swelling/itching, induration, headache, diarrhea, hypertension (Teichman RCTs); also flushing, water retention, insomnia reported; A trial participant died of myocardial infarction after 11th dose (attributed to pre-existing coronary disease), program stopped; Serious adverse events including increased heart rate and a systemic vasodilatory reaction. The list is not complete, and few listed risks does not mean a compound is safe.
How strong is the evidence for CJC-1295 with DAC?
Evidence label: Early human. Small human PK/PD RCTs showing GH/IGF-1 rise; no clinical outcome data; development abandoned.
What else is CJC-1295 with DAC called?
Names used for it include DAC:GRF, CJC-1295 with DAC.
Does humanpeptides.fyi recommend CJC-1295 with DAC?
No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician.